Overall, the increased relative availability of IL-13 due to dupilumab’s blockade of IL-4Rα may increase IL-13 binding to its IL-13Rα2 decoy receptor, which may have downstream efects that promote CTCL progression [6, 31]. This evidence concerns the gene IL13 and primary cutaneous T-cell non-Hodgkin lymphoma.